Star Scientific (STSI) 0.58 $STSI
Equities Lead Investor Sentiment -- Revolution Lighting Technologies, Rock Creek Pharmaceuticals, Schnitzer Steel, Select Comfort and Sigma-Aldrich
PR Newswire - Mon Dec 15, 11:14AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
STSI: 0.58 (-0.05), RVLT: 1.14 (-0.02)
Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ
PR Newswire - Thu Dec 11, 3:32PM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it received notification from the Nasdaq Stock Market, Inc. granting a six-month extension of its Nasdaq listing. The Company has until April 27, 2015 to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive days to maintain compliance with Nasdaq listing requirements. The extension is also subject to the condition that the Company provide certain written updates to Nasdaq during the extension period and that Rock Creek file, on or before February 23, 2015, a preliminary proxy statement for a shareholder meeting for a reverse stock split proposal.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015
PR Newswire - Fri Nov 21, 7:30AM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Reports Third Quarter 2014 Results and Provides Business Update
PR Newswire - Mon Nov 10, 4:00PM CST
Rock Creek Pharmaceuticals, Inc., (RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today its financial results for the third quarter ended September 30, 2014 and provided a business update. The Company's Form 10-Q was filed with the Securities Exchange Commission.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Announces Presentation of Four Anatabine Projects at Neuroscience 2014
PR Newswire - Thu Oct 23, 8:06AM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that abstracts outlining four separate preclinical studies evaluating anatabine, the primary constituent in the Company's lead investigational compound anatabine citrate, have been accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. This meeting is the premier event in the field, typically attracting approximately 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response
PR Newswire - Fri Sep 12, 7:30AM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed Investigational New Drug Application (INDA).
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
PR Newswire - Mon Aug 11, 3:20PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
PR Newswire - Wed Aug 06, 12:04PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
PR Newswire - Mon Aug 04, 1:49PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
PR Newswire - Thu Jul 31, 2:31PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Consumer Staples Stocks Technical Snapshot -- Procter and Gamble, Clorox, Rock Creek Pharma, Nu Skin Enterprises, and Estee Lauder Cos
PR Newswire - Wed Jul 23, 7:50AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Consumer Staples Sector Index ended the day at 461.51, down 0.20%, while the index has advanced 3.04% in the previous three months. Investor-Edge has initiated coverage on the following equities: The Procter & Gamble Company (NYSE: PG), The Clorox Company (NYSE: CLX), Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI), Nu Skin Enterprises Inc. (NYSE: NUS), and The Estee Lauder Companies Inc. (NYSE: EL). Free research on these five companies can be accessed at:
STSI: 0.58 (-0.05), CLX: 109.00 (+0.74), NUS: 56.92 (-1.30), RCPI: 0.16 (unch), PG: 85.90 (-0.13), EL: 82.49 (+1.58)
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
PR Newswire - Fri Jul 11, 3:30PM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"
, has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND" application before granting the Company permission to start its clinical trial in the US.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Equities Lead Investor Sentiment -- Revolution Lighting Technologies, Rock Creek Pharmaceuticals, Schnitzer Steel, Select Comfort and Sigma-Aldrich
PR Newswire - Mon Dec 15, 11:14AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations. Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
STSI: 0.58 (-0.05), RVLT: 1.14 (-0.02)
Rock Creek Pharmaceuticals Announces Listing Extension on NASDAQ
PR Newswire - Thu Dec 11, 3:32PM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it received notification from the Nasdaq Stock Market, Inc. granting a six-month extension of its Nasdaq listing. The Company has until April 27, 2015 to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive days to maintain compliance with Nasdaq listing requirements. The extension is also subject to the condition that the Company provide certain written updates to Nasdaq during the extension period and that Rock Creek file, on or before February 23, 2015, a preliminary proxy statement for a shareholder meeting for a reverse stock split proposal.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015
PR Newswire - Fri Nov 21, 7:30AM CST
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Reports Third Quarter 2014 Results and Provides Business Update
PR Newswire - Mon Nov 10, 4:00PM CST
Rock Creek Pharmaceuticals, Inc., (RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today its financial results for the third quarter ended September 30, 2014 and provided a business update. The Company's Form 10-Q was filed with the Securities Exchange Commission.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Announces Presentation of Four Anatabine Projects at Neuroscience 2014
PR Newswire - Thu Oct 23, 8:06AM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that abstracts outlining four separate preclinical studies evaluating anatabine, the primary constituent in the Company's lead investigational compound anatabine citrate, have been accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. This meeting is the premier event in the field, typically attracting approximately 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response
PR Newswire - Fri Sep 12, 7:30AM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today it has received a written response from the U.S. Food and Drug Administration (FDA) in response to the New Dietary Ingredient Notification (NDIN) for the formulations of Anatabloc® and CigRx® submitted by the Company in June 2014. The letter indicated that the FDA considers anatabine citrate, a principal ingredient in these products, to be a drug, because anatabine citrate is intended to provide anti-inflammatory support, and is the subject of a previously filed Investigational New Drug Application (INDA).
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
PR Newswire - Mon Aug 11, 3:20PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI), a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that it filed with the Securities Exchange Commission its Form 10-Q for the second quarter ended June 30, 2014. The company has also announced a clinical and regulatory update.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
PR Newswire - Wed Aug 06, 12:04PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has made two key independent appointments to the Company's Board of Directors with the recent election of Ms. Lee M. Canaan, CFA and Mr. Edward J. McDonnell, MPH. as new directors.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
PR Newswire - Mon Aug 04, 1:49PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company has been selected to present at the Next Generation Track at BioPharm America 2014 in Boston (Sept. 22-24, 2014) at The Boston Marriott Copley Place.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
PR Newswire - Thu Jul 31, 2:31PM CDT
Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has initiated the development of its lead molecule, Anatabine Citrate, in Europe; and that it has selected Quotient Clinical, The Translational Pharmaceutics Company, based in the United Kingdom (UK) to run its early development programs.
STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
Consumer Staples Stocks Technical Snapshot -- Procter and Gamble, Clorox, Rock Creek Pharma, Nu Skin Enterprises, and Estee Lauder Cos
PR Newswire - Wed Jul 23, 7:50AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Consumer Staples Sector Index ended the day at 461.51, down 0.20%, while the index has advanced 3.04% in the previous three months. Investor-Edge has initiated coverage on the following equities: The Procter & Gamble Company (NYSE: PG), The Clorox Company (NYSE: CLX), Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI), Nu Skin Enterprises Inc. (NYSE: NUS), and The Estee Lauder Companies Inc. (NYSE: EL). Free research on these five companies can be accessed at:
STSI: 0.58 (-0.05), CLX: 109.00 (+0.74), NUS: 56.92 (-1.30), RCPI: 0.16 (unch), PG: 85.90 (-0.13), EL: 82.49 (+1.58)
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
PR Newswire - Fri Jul 11, 3:30PM CDT
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration ("FDA"
, has notified the Company that the agency will provide comments on RCP's Investigational New Drug ("IND" application before granting the Company permission to start its clinical trial in the US. STSI: 0.58 (-0.05), RCPI: 0.16 (unch)
